Opinion|Videos|December 23, 2024
Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study
Panelists discuss how the CLARIFY-MS extension study revealed stable cognitive function 4 years post cladribine, highlighting the potential of early treatment to preserve cognitive capabilities in multiple sclerosis (MS) patients. Cognitive assessments remain crucial for monitoring disease progression and tailoring patient management.
Advertisement
Video content above is prompted by the following:
- Cognition data was examined in the CLARIFY-MS extension study in patients 4 years after initial dose of cladribine. Please discuss changes in Symbol Digit Modalities Test (SDMT) scores over time and what these results mean for the cognitive function of the patient.
- What are your impressions of long-term cognition data with other high-efficacy therapies?
- How do you utilize cognitive data in your practice?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
2
This Week on NeurologyLive® — September 15, 2025
3
2025 Women in Neurology Conference: Educating, Mentoring, and Networking
4
NeurologyLive® Brain Games: September 14, 2025
5